Terms ending in 2034
Every in-force patent on Actelion Pharmaceuticals Ltd's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,617,250 | PYRIDIN-4-YL Derivatives In force · High confidence | Viatris Asia Pacific Pte. Ltd. | In force | High confidence | |
| US 9,422,249 | Preparation of Pyrimidine Intermediates Useful for the Manufacture of Macitentan In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 9,676,731 | Preparation of Pyrimidine Intermediates Useful for the Manufacture of Macitentan In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 9,556,125 | Process for Preparing a Pyrimidine Intermediate In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 10,259,807 | 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE Derivatives In force · High confidence | Idorsia Pharmaceuticals Ltd. | In force | High confidence | |
| US 10,189,839 | Tricyclic Imidazole Compounds as Inhibitors of Tryptophan Hydroxylase In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 9,790,208 | Crystalline Salt Form of (S)-(2-(6-Chloro-7-Methyl-1H-BENZO[D]IMIDAZOL-2-YL)-2-Methylpyrrolidin-1-YL) (5-Methoxy-2-(2H-1,2,3-Triazol-2-YL)PHENYL)METHANONE as Orexin Receptor Antagonist In force · High confidence | Idorsia Pharmaceuticals Ltd. | In force | High confidence | |
| US 9,914,720 | Crystalline Form of (S)-(2-(6-Chloro-7-Methyl-1H-BENZO[D]IMIDAZOL-2-YL)-2-Methylpyrrolidin-1 -YL)(5-Methoxy-2-(2H-1,2,3-Triazol-2-YL)PHENYL)METHANONE and Its Use as Orexin Receptor Antagonists In force · High confidence | Idorsia Pharmaceuticals Ltd. | In force | High confidence | |
| US 10,023,560 | Crystalline Salt Form of (S)-(2-(6-Chloro-7-Methyl-1H-BENZO[D]IMIDAZOL-2-YL)-2-Methylpyrrolidin-1-YL)(5-Methoxy-2-(2H-1,2,3-Triazol-2-YL)PHENYL)METHANONE as Orexin Receptor Antagonist In force · High confidence | Idorsia Pharmaceuticals Ltd. | In force | High confidence | |
| US 9,914,721 | Use of Benzimidazole-Proline Derivatives In force · High confidence | Idorsia Pharmaceuticals Ltd. | In force | High confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Actelion Pharmaceuticals Ltd.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.